3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
InfuSystems Holdings's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was -166.47%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for InfuSystems Holdings's 3-Year ROIIC % or its related term are showing as below:
INFU's 3-Year ROIIC % is ranked worse than 90.84% of 797
companies
in the Medical Devices & Instruments industry
Industry Median: 1.47
vs INFU: -166.47
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
InfuSystems Holdings 3-Year ROIIC % Related Terms
InfuSystems Holdings 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for InfuSystems Holdings's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INFU vs QTRX, LUCD, APYX: 3-Year ROIIC % Comparison
For the Medical Devices subindustry, InfuSystems Holdings's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InfuSystems Holdings 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, InfuSystems Holdings's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where InfuSystems Holdings's 3-Year ROIIC % falls into.
InfuSystems Holdings's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 7.435696 (Dec. 2025) - 0.229079 (Dec. 2022) )
/
( 86.553 (Dec. 2025) - 90.882 (Dec. 2022) )
=
7.206617
/
-4.329
=
-166.47%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
InfuSystems Holdings (INFU) has a 3-Year ROIIC % of -166.47 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on InfuSystems Holdings and its competitors. According to the industry distribution chart, InfuSystems Holdings ranks #724 out of 797 companies in the Medical Devices & Instruments industry, placing it in the top 90.8%.
Is InfuSystems Holdings' 3-Year ROIIC % too high?
InfuSystems Holdings' current 3-Year ROIIC % is -166.47. Based on the distribution chart, InfuSystems Holdings ranks #724 out of 797 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, InfuSystems Holdings has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does InfuSystems Holdings' 3-Year ROIIC % compare to QTRX and LUCD?
According to the Medical Devices & Instruments industry distribution chart, InfuSystems Holdings ranks #724 out of 797 companies for 3-Year ROIIC %. This places InfuSystems Holdings in the lower half of its industry. The industry median 3-Year ROIIC % is 1.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.47, based on 797 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on InfuSystems Holdings and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InfuSystems Holdings's current 3-Year ROIIC % is -166.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InfuSystems Holdings stock overvalued right now?
Based on GuruFocus' analysis, InfuSystems Holdings (INFU) is currently considered Fairly Valued. The stock's GF Value™ is $9.45, compared to a current price of $9.68 — trading 2.4% above its estimated fair value. The current 3-Year ROIIC % is -166.47. InfuSystems Holdings' overall GF Score™ is 87/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For InfuSystems Holdings (INFU), the current 3-Year ROIIC % is -166.47 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InfuSystems Holdings (INFU) Overvalued in 2026?
Based on GuruFocus' analysis, InfuSystems Holdings stock appears to be overvalued.
The current stock price of $9.68 is trading 2.4% above its estimated GF Value™ of $9.45.
GuruFocus considers InfuSystems Holdings to be Fairly Valued.
Key valuation signals for INFU:
3-Year ROIIC %: -166.47
GF Value™: $9.45 vs. price of $9.68 (2.4% above fair value)
No single metric tells the full story. See the INFU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. The company's services are provided under two-reportable segments: Patient Services and Device Solutions. Maximum revenue is generated from its Patient Services segment, which provides Durable Medical Equipment (DME) and treatment consumables, handles order and delivery logistics, provides 24/7 nursing support relating to the provided equipment, assumes responsibility for third-party payer Durable Medical Equipment billing, and handles biomedical services for the Durable Medical Equipment. The Device Solutions segment includes equipment rental and sales, consumable sales, and biomedical support services.
87GF Score
Get the complete analysis for INFU
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INFU has been successfully added to your 
